These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 26028398

  • 21. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E.
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [Abstract] [Full Text] [Related]

  • 22. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 24. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F.
    Nephron Clin Pract; 2014 Sep; 126(1):14-8. PubMed ID: 24434725
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pharmacological treatment of type 2 diabetes.
    Hermans MP, Buysschaert M.
    Acta Clin Belg; 2004 Sep; 59(2):59-66. PubMed ID: 15224468
    [No Abstract] [Full Text] [Related]

  • 31. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, Ikenaga Y, Nakamaru Y, Hikida K, Saito A, Arakawa K, Oka K, Ueta K, Shiotani M.
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [Abstract] [Full Text] [Related]

  • 32. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 33. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F, Lüscher TF.
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [Abstract] [Full Text] [Related]

  • 34. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
    Tahrani AA, Barnett AH, Bailey CJ.
    Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
    [Abstract] [Full Text] [Related]

  • 35. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM.
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [Abstract] [Full Text] [Related]

  • 36. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
    Nauck MA.
    Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
    [No Abstract] [Full Text] [Related]

  • 37. What to add in with metformin in type 2 diabetes?
    Petrie JR, Adler A, Vella S.
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [Abstract] [Full Text] [Related]

  • 38. [Drug treatment of type 2 diabetes].
    Tielmans A, Laloi-Michelin M, Coupaye M, Virally M, Meas T, Guillausseau PJ.
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [Abstract] [Full Text] [Related]

  • 39. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK.
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [Abstract] [Full Text] [Related]

  • 40. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ, Paquot N.
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.